The cash infusion eliminates near-term financing risk and provides a clear catalyst path for EDG-7500. Traders should watch for Phase 3 initiation in Q4 2026 and potential milestone payments from Servier. The GRAND CANYON pivotal cohort top-line data for sevasemten (now owned by Servier) is also expected in Q4 2026, which could trigger milestone payments to Edgewise.
Price Chart
Executive Summary
Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for total potential consideration of up to $2.65 billion. The transaction transforms Edgewise into a cardiovascular-focused company and is expected to fully fund EDG-7500 development through potential approval. The closing removes deal risk and provides a strong cash runway.
Key Facts
- Edgewise received $1.55 billion in upfront cash from Servier for the sevasemten program.
- Up to $1.1 billion in additional regulatory and commercial milestones, for aggregate potential consideration of up to $2.65 billion.
- Transaction closed on July 10, 2026, as previously announced on June 1, 2026.
- Company is now a cardiovascular-focused biopharma with pipeline including EDG-7500, EDG-15400, and EDG-003.
- Phase 3 trial of EDG-7500 expected to initiate in Q4 2026; Phase 2 trial of EDG-15400 in HFpEF on track.
- Upfront proceeds plus existing cash expected to fully fund EDG-7500 development through potential approval.
Financial Impact
Edgewise receives $1.55 billion upfront cash, strengthening balance sheet by approximately 32% of pre-deal market cap ($4.9B). Total potential consideration up to $2.65 billion.
Risk Factors
- Milestone payments are contingent on regulatory and commercial success of sevasemten under Servier.
- Edgewise is now dependent on earlier-stage cardiovascular pipeline (EDG-7500, EDG-15400) with no approved products.
- Clinical trial risks for EDG-7500 and EDG-15400 could delay or derail the pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082902 |
| Document: tm2620181d1_ex99-1.htm | 0001104659-26-082902 |
| Document: 0001104659-26-082902-index-headers.html | 0001104659-26-082902 |
| Document: 0001104659-26-082902-index.html | 0001104659-26-082902 |
| Document: 0001104659-26-082902.txt | 0001104659-26-082902 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 6, 2026 8w ago | 8-K | $44.42 $41.95 | ▼ −5.56% | ▼ −6.16% | $41.22 (−7.20%) |
Jul 13, 2026 11w ago | 8-K | $41.27 $44.58 | ▲ +8.02% | ▲ +4.84% | $41.22 (−0.12%) |
Jun 1, 2026 17w ago | 8-K | $40.26 $40.63 | ▲ +0.92% | ▲ +2.22% | $41.22 (+2.38%) |
May 7, 2026 21w ago | 8-K | $35.58 $36.21 | ▲ +1.77% | ▼ −1.37% | $41.22 (+15.85%) |
Apr 23, 2026 23w ago | DEFA14A | $31.58 $32.69 | ▲ +3.51% | ▼ −0.51% | $41.22 (+30.53%) |
Mar 27, 2026 26w ago | 144 | $30.28 $30.99 | ▲ +2.34% | ▼ −10.25% | $41.22 (+36.13%) |
Feb 26, 2026 31w ago | 8-K | $29.66 $31.65 | ▲ +6.71% | ▲ +13.11% | $41.22 (+38.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access